Celldex Therapeutics, Inc.

Informe acción NasdaqCM:CLDX

Capitalización de mercado: US$2.4b

Salud financiera de hoja de balance de Celldex Therapeutics

Salud financiera controles de criterios 6/6

Celldex Therapeutics tiene un patrimonio de los accionistas total de $429.2M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $465.6M y $36.5M respectivamente.

Información clave

0%

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de interesesn/a
EfectivoUS$823.85m
PatrimonioUS$838.61m
Total pasivoUS$30.23m
Activos totalesUS$868.85m

Actualizaciones recientes sobre salud financiera

Recent updates

We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth

Jul 07
We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth

An Intrinsic Calculation For Celldex Therapeutics, Inc. (NASDAQ:CLDX) Suggests It's 34% Undervalued

Apr 21
An Intrinsic Calculation For Celldex Therapeutics, Inc. (NASDAQ:CLDX) Suggests It's 34% Undervalued

Companies Like Celldex Therapeutics (NASDAQ:CLDX) Are In A Position To Invest In Growth

Feb 27
Companies Like Celldex Therapeutics (NASDAQ:CLDX) Are In A Position To Invest In Growth

We're Not Very Worried About Celldex Therapeutics' (NASDAQ:CLDX) Cash Burn Rate

Sep 07
We're Not Very Worried About Celldex Therapeutics' (NASDAQ:CLDX) Cash Burn Rate

Celldex begins dosing in mid-stage study of barzolvolimab for skin disorder

Jul 21

Celldex: Barzolvolimab Plus Bispecific Antibodies Advancement

Jul 14

Celldex Therapeutics (NASDAQ:CLDX) Is In A Good Position To Deliver On Growth Plans

May 25
Celldex Therapeutics (NASDAQ:CLDX) Is In A Good Position To Deliver On Growth Plans

Are Investors Undervaluing Celldex Therapeutics, Inc. (NASDAQ:CLDX) By 31%?

Feb 03
Are Investors Undervaluing Celldex Therapeutics, Inc. (NASDAQ:CLDX) By 31%?

Celldex: Pipeline Of Drug Candidates Is Worth A Look

Feb 01

Celldex Therapeutics: A Best Price-Positioned Biotech Stock As Seen By Market-Makers

Sep 23

We Think Celldex Therapeutics (NASDAQ:CLDX) Can Easily Afford To Drive Business Growth

Sep 15
We Think Celldex Therapeutics (NASDAQ:CLDX) Can Easily Afford To Drive Business Growth

Celldex: Powerful Medicines To Yield Further Upsides

Jul 08

Here's Why We're Not Too Worried About Celldex Therapeutics' (NASDAQ:CLDX) Cash Burn Situation

May 12
Here's Why We're Not Too Worried About Celldex Therapeutics' (NASDAQ:CLDX) Cash Burn Situation

We're Hopeful That Celldex Therapeutics (NASDAQ:CLDX) Will Use Its Cash Wisely

Jan 27
We're Hopeful That Celldex Therapeutics (NASDAQ:CLDX) Will Use Its Cash Wisely

The Celldex Therapeutics (NASDAQ:CLDX) Share Price Is Up 626% And Shareholders Are Delighted

Dec 23
The Celldex Therapeutics (NASDAQ:CLDX) Share Price Is Up 626% And Shareholders Are Delighted

Dosing underway in Celldex's CDX-0159 study in skin allergy

Dec 09

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($431.7M) de CLDX superan a sus pasivos a corto plazo ($31.1M).

Pasivo a largo plazo: Los activos a corto plazo de CLDX ($431.7M) superan a sus pasivos a largo plazo ($5.3M).


Historial y análisis de deuda-patrimonio

Nivel de deuda: CLDX está libre de deudas.

Reducción de la deuda: CLDX no tenía deudas hace 5 años.


Hoja de balance


Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: CLDX tiene suficiente cash runway para más de 3 años basándose en su flujo de caja libre actual.

Pronóstico de cash runway: CLDX dispone de suficiente cash runway para más de 3 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 9.9% cada año


Descubre empresas con salud financiera